DK3204022T3 - Placenta-afledte adhærente celle-exosomer og anvendelser deraf - Google Patents

Placenta-afledte adhærente celle-exosomer og anvendelser deraf Download PDF

Info

Publication number
DK3204022T3
DK3204022T3 DK15849339.5T DK15849339T DK3204022T3 DK 3204022 T3 DK3204022 T3 DK 3204022T3 DK 15849339 T DK15849339 T DK 15849339T DK 3204022 T3 DK3204022 T3 DK 3204022T3
Authority
DK
Denmark
Prior art keywords
placenta
adherent cell
derived adherent
cell exosomes
exosomes
Prior art date
Application number
DK15849339.5T
Other languages
Danish (da)
English (en)
Inventor
Eric Law
Andrew Morschauser
Aleksandar Francki
Jennifer Paredes
Kathy E Karasiewicz-Mendez
Allan Reduta
Ivana Djuretic
Vladimir Jankovic
Original Assignee
Celularity Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55653751&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3204022(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celularity Inc filed Critical Celularity Inc
Application granted granted Critical
Publication of DK3204022T3 publication Critical patent/DK3204022T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0668—Mesenchymal stem cells from other natural sources
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/02—Coculture with; Conditioned medium produced by embryonic cells
    • C12N2502/025—Coculture with; Conditioned medium produced by embryonic cells extra-embryonic cells, e.g. amniotic epithelium, placental cells, Wharton's jelly

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK15849339.5T 2014-10-09 2015-10-08 Placenta-afledte adhærente celle-exosomer og anvendelser deraf DK3204022T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462062046P 2014-10-09 2014-10-09
PCT/US2015/054629 WO2016057755A1 (en) 2014-10-09 2015-10-08 Placenta-derived adherent cell exosomes and uses thereof

Publications (1)

Publication Number Publication Date
DK3204022T3 true DK3204022T3 (da) 2021-03-08

Family

ID=55653751

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15849339.5T DK3204022T3 (da) 2014-10-09 2015-10-08 Placenta-afledte adhærente celle-exosomer og anvendelser deraf

Country Status (8)

Country Link
US (3) US20170252379A1 (https=)
EP (1) EP3204022B1 (https=)
JP (3) JP2017536096A (https=)
CN (2) CN107106615A (https=)
AU (2) AU2015330855A1 (https=)
CA (1) CA2964114A1 (https=)
DK (1) DK3204022T3 (https=)
WO (1) WO2016057755A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10900034B2 (en) 2014-12-03 2021-01-26 Agilent Technologies, Inc. Guide RNA with chemical modifications
EP3280803B1 (en) 2015-04-06 2021-05-26 The Board of Trustees of the Leland Stanford Junior University Chemically modified guide rnas for crispr/cas-mediated gene regulation
US20180177727A1 (en) 2015-06-10 2018-06-28 Board Of Regents, The University Of Texas System Use of exosomes for the treatment of disease
CA3023349A1 (en) * 2016-05-16 2017-11-23 Exostem Biotec Ltd. Mesenchymal stem cell and use thereof for treatment of muscle injury and muscle-associated diseases
US10767175B2 (en) 2016-06-08 2020-09-08 Agilent Technologies, Inc. High specificity genome editing using chemically modified guide RNAs
AU2018266111B2 (en) 2017-05-08 2024-11-07 Flagship Pioneering Innovations V, Inc. Compositions for facilitating membrane fusion and uses thereof
US20200163993A1 (en) * 2017-05-09 2020-05-28 Saint Louis University Treatment of cancer and infectious diseases with natural killer (nk) cell-derived exosomes
US20200188440A1 (en) * 2017-05-16 2020-06-18 Exostem Biotec Ltd. Methods of inhibiting aging and treating aging-related disorders
IL270864B2 (en) * 2017-05-24 2025-01-01 Nanosomix Inc Identification of biomarkers on vesicles for diagnosis and prognosis of diseases and disorders
KR102109950B1 (ko) * 2017-06-02 2020-05-12 (주)엑솔런스바이오테크놀로지 체외충격파를 이용한 세포외소포체 내로의 표적물질 전달방법
EP3672573A4 (en) 2017-08-25 2021-05-26 Codiak BioSciences, Inc. PREPARATION OF THERAPEUTIC EXOSOMES USING MEMBRANE PROTEINS
KR102335710B1 (ko) * 2017-10-31 2021-12-07 (주)아모레퍼시픽 유산균 유래의 세포밖 베지클을 포함하는 면역조절용 조성물
GB201718681D0 (en) * 2017-11-13 2017-12-27 Evox Therapeutics Ltd Protein engineered extracellular vesicles
CA3082880A1 (en) * 2017-11-16 2019-05-23 Celularity Inc. Cultivation of placenta to isolate exosomes
WO2019118817A1 (en) * 2017-12-14 2019-06-20 Mayo Foundation For Medical Education And Research Purified exosome products, method of making, and methods of using
AU2018394238A1 (en) 2017-12-28 2020-06-18 Lonza Sales Ag Exosomes for immuno-oncology and anti-inflammatory therapy
CN112384200A (zh) * 2018-01-30 2021-02-19 希斯托金公司 低氧条件下培养的细胞衍生的胞外囊泡及其用途
KR102235141B1 (ko) * 2018-06-19 2021-04-05 푸와이 하스피틀, 차이니즈 아카데미 오브 메디컬 사이언시즈 앤드 페킹 유니언 메디컬 칼리지 약물 전처리에 기초한 간엽 줄기세포 유래 엑소좀 제조방법
AU2019312212B2 (en) * 2018-07-24 2024-10-10 Mayo Foundation For Medical Education And Research Compositions and methods involving transforming extracellular vesicles
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CN109554341B (zh) * 2018-12-18 2021-11-19 深圳先进技术研究院 无创超声处理细胞在制备外泌体中的应用、外泌体及其制备方法和应用
CN110093274B (zh) * 2019-05-13 2020-08-11 山东大学 一种增加细胞产生的细胞外囊泡数量的挤压装置及其应用
PH12021553167A1 (en) * 2019-06-19 2022-08-15 Celularity Inc Exosomes for disease treatment
WO2021210852A1 (ko) * 2020-04-14 2021-10-21 (주)녹십자웰빙 태반 유래 물질을 포함하는 항바이러스 조성물
KR20220030552A (ko) * 2020-09-03 2022-03-11 (주)녹십자웰빙 태반 유래 엑소좀을 포함하는 간세포 증식 또는 항염증 효능 조성물
JP2024534945A (ja) 2021-09-10 2024-09-26 アジレント・テクノロジーズ・インク 化学修飾を有するプライム編集のためのガイドｒｎａ
WO2024102969A1 (en) * 2022-11-10 2024-05-16 Board Of Regents, The University Of Texas System Use of fecal derivatives and fecal derived extracellular vesicles to enhance immunity
CN117050936A (zh) * 2023-07-11 2023-11-14 清华大学 新亚群的人脐带间充质干细胞、其外泌体、制剂和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2316918B1 (en) 2001-02-14 2015-07-01 Anthrogenesis Corporation Post-partum mammalian placenta, its use and placental stem cells therefrom
PL2471907T3 (pl) 2005-12-29 2019-07-31 Celularity, Inc. Populacje komórek macierzystych łożyska
CA2734237C (en) 2008-08-20 2019-07-02 Anthrogenesis Corporation Treatment of stroke using isolated placental cells
RU2539786C2 (ru) * 2008-09-02 2015-01-27 Плуристем Лтд. Выращенные в прикрепленной к субстрату культуре клетки из ткани плаценты и их использование при лечении
GB2463401B (en) * 2008-11-12 2014-01-29 Caris Life Sciences Luxembourg Holdings S A R L Characterizing prostate disorders by analysis of microvesicles
FR2950360B1 (fr) * 2009-09-22 2011-11-25 Centre Nat Rech Scient Procede d'imagerie cellulaire pour la visualisation de la biogenese des microarns dans les cellules
DK2556145T3 (en) * 2010-04-07 2016-11-07 Anthrogenesis Corp Angiogenesis using placental stem cells
EP2691101A2 (en) * 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
EP2721179A4 (en) * 2011-06-16 2014-10-01 Caris Life Sciences Luxembourg Holdings S A R L BIOMARKER COMPOSITIONS AND METHOD THEREFOR
US11391741B2 (en) * 2011-12-22 2022-07-19 Theoria Science Inc. Method of exosome analysis, reagent for exosome analysis, and analyzer for exosome
US9427450B2 (en) * 2012-01-31 2016-08-30 Xon Cells, Inc. Therapeutic immune modulation by stem cell secreted exosomes
WO2014022852A1 (en) * 2012-08-03 2014-02-06 Aptamir Therapeutics, Inc. Cell-specific delivery of mirna modulators for the treatment of obesity and related disorders
AU2013302799B2 (en) * 2012-08-13 2018-03-01 Cedars-Sinai Medical Center Exosomes and micro-ribonucleic acids for tissue regeneration
DK2931897T3 (en) * 2012-12-12 2018-02-05 Broad Inst Inc CONSTRUCTION, MODIFICATION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION AND THERAPEUTICAL APPLICATIONS
EP2935628B1 (en) * 2012-12-19 2018-03-21 Caris Life Sciences Switzerland Holdings GmbH Compositions and methods for aptamer screening
EP3608022A1 (en) * 2013-03-15 2020-02-12 The Trustees of Princeton University Methods and devices for high throughput purification

Also Published As

Publication number Publication date
AU2021204332A1 (en) 2021-07-22
JP2023011580A (ja) 2023-01-24
JP2017536096A (ja) 2017-12-07
CN107106615A (zh) 2017-08-29
EP3204022A1 (en) 2017-08-16
WO2016057755A1 (en) 2016-04-14
US20170252379A1 (en) 2017-09-07
US11173182B1 (en) 2021-11-16
EP3204022B1 (en) 2020-12-02
CA2964114A1 (en) 2016-04-14
EP3204022A4 (en) 2018-06-13
AU2015330855A1 (en) 2017-04-27
CN116731958A (zh) 2023-09-12
US20220241347A1 (en) 2022-08-04
JP2021040635A (ja) 2021-03-18

Similar Documents

Publication Publication Date Title
DK3204022T3 (da) Placenta-afledte adhærente celle-exosomer og anvendelser deraf
DK3597742T3 (da) Car-udtrykkende vektor og car-udtrykkende t-celler
DK3218358T3 (da) Ifluorometyl-aminopyridiner og difluorometyl-aminopyrimidiner
ZA201605858B (en) Novel polysaccharide and uses thereof
DK3212255T3 (da) Selvorienterende sprøjte og sprøjtegrænseflade
HUE046262T2 (hu) Sejt
IL247014A0 (en) 6-heteroaryloxy and 6-aryloxy-quinoline-2-carboxamides and their use
DK3157552T3 (da) Syntac-polypeptider og anvendelser deraf
GB201413355D0 (en) Compositons and methods
IL249970B (en) Gamma delta t cells and uses thereof
DK3015526T3 (da) Hydrofluorolefinbaseret sammensætning og anvendelse deraf
DK3161139T3 (da) Tlr-4-specifikke aptamerer og anvendelser heraf
DK3209773T3 (da) Prolintolerante tripeptidylpeptidaser og anvendelser deraf
DK3101760T3 (da) Opladningsfremgangsmåde og system
DK3138048T3 (da) Kodede celler og cellearrays
DK3131577T3 (da) Modificerede værtsceller og anvendelser deraf
DK3321279T3 (da) Exenatidmodificeringsmiddel og anvendelse deraf
DK3365321T3 (da) Solabegron-zwitterion og anvendelser deraf
DK3337506T3 (da) Kombinationer og anvendelser deraf
SG11201610514SA (en) Bioreactor and uses thereof
DK3101770T3 (da) Strømadapter og terminal
DK3180335T3 (da) Cytokrom-p450-inhibitorer og anvendelser deraf
DK3107376T3 (da) Svampelinje b12998-s39 og fremgangsmåder dertil og anvendelser herfor
GB201408091D0 (en) Methods and uses
GB201616232D0 (en) Novel cell line and uses thereof